Alerta

INHIBITOR OF Aβ175 OLIGOMERS/AGGREGATES AND USE THEREOF

Resumen de: WO2026076634A1

Provided are Aβ375 related oligomers/aggregates in human brains and anti-Aβ3175 related oligomers/aggregates antibodies thereof. In addition, the using of anti-Aβ3175 related oligomers/aggregates antibodies for the treatment of Alzheimer's disease (AD) is also provided.

METHOD FOR QUANTIFYING DOPA DECARBOXYLASE IN BIOLOGICAL SAMPLE

Resumen de: WO2026079284A1

Disclosed is a method for quantifying DOPA decarboxylase in a biological sample. The method includes bringing the biological sample into contact with a first anti-DOPA decarboxylase antibody or an antigen-binding fragment thereof.

DIAGNOSTIC METHOD OF DETERMINING THE PRESENCE OF A LABEL-FREE ANTIBODY-ANTIGEN COMPLEX OF INTEREST IN A BIOLOGICAL SAMPLE

Resumen de: WO2026077769A1

Diagnostic method (100) of determining the presence of a label-free antibody-antigen complex of interest in a biological sample: Providing (101) a trained model based on a training data set processed by multivariate statistics and a machine learning algorithm, wherein the training data set comprises: immunoassay training data of the labeled antibody-antigen complex obtained from at least one immunoassay technique; spectral training data comprising one or more training vibrational spectra of the labeled and/or label-free antibody-antigen complex obtained from at least one vibrational spectroscopy technique; Recording (102) at least one sample vibrational spectrum of a biological sample using the at least one vibrational spectroscopy technique; and Applying (103) the trained model onto the at least one sample vibrational spectrum and determine whether or not the label-free antibody-antigen complex is present in the biological sample.

INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS

Resumen de: US20260102391A1

The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and/or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.

PRODUCTS AND METHODS FOR THE RAPID SCREENING OF A BRAIN CELL-BASED CULTURE

Resumen de: WO2026080738A1

A method for the rapid screening of responsiveness of a brain cell-based culture to a therapeutic, wherein the method includes digesting brain tissue or brain tumor tissue into small cell clusters; filtering the digested brain tissue or brain tumor tissue to obtain small cell clusters; mixing the small cell clusters with an extracellular matrix (ECM) to generate a suspension of cells; generating a droplet comprising the suspension of cells in an oil using an oil-emulsion microfluidic system; demulsifying the droplet to separate the cells from the oil; isolating and/or collecting the droplet comprising a single cell or multiple cells; treating the cell or cells in the droplet with a therapeutic; and detecting a response of the cell or cells to the therapeutic, and optionally, determining that the therapeutic is effective. A brain cell-based culture or organoid made by digesting brain tissue or brain tumor tissue into small cell clusters; filtering the digested brain tissue or brain tumor tissue to obtain small cell clusters; mixing the small cell clusters with an extracellular matrix (ECM) to generate a suspension of cells; generating a droplet comprising the suspension of cells in an oil using an oil-emulsion microfluidic system; demulsifying the droplet to separate the cells from the oil; and isolating and/or collecting the droplet comprising a single cell or multiple cells; and, if an organoid is required, growing the cell or cells in the droplet in culture for a period of

LIPID-METABOLOME-RELATED BIOMARKERS FOR ADHD

Resumen de: WO2026077864A1

The amount of certain metabolomic markers from the lipid metabolism can be used for the highly specific and sensitive in-vitro diagnosis of ADHD.

BIOELECTRIC CHARACTERIZATION OF SENESCING HUMAN KERATINOCYTES

Resumen de: WO2026080749A1

Systems and methods for measuring cell senescence are provided herein.

METHODS FOR KIDNEY TRANSPLANT TESTING

Resumen de: WO2026080556A1

Methods for assessing the likelihood of delayed graft function (DGF) of a donor kidney in a kidney transplant recipient are provided. Additionally, methods for determining the likelihood of requiring dialysis in a kidney transplant recipient are provided. Such methods include measuring expression of at least one gene in a sample from the kidney for transplant or from the transplanted kidney.

METHODS FOR IDENTIFYING SUBJECTS AT RISK OF THROMBOSIS OR MALIGNANCY

Resumen de: US20260104419A1

Disclosed herein are methods for detecting or determining an amount, quantity, concentration and/or level of an anti-transcription factor A, mitochondrial (TFAM) antibody, such as an anti-human TFAM antibody, in one or more biologics samples obtained from a subject. In some aspects, the methods relate to identifying a subject suffering from systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome that is at risk of thrombosis, malignancy, death or any combination thereof.

MICROVIRIDAE BACTERIOPHAGES AND ANTHRANILIC ACID IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FOOD INTAKE RELATED DISORDERS

Resumen de: WO2026078222A1

The present invention relates to methods for diagnosis and monitoring of food addiction, obesity and related disorders, as well as for the evaluation of treatments directed to said disorders, based on the determination and comparison of Microviridae bacteriophages, preferably Gokushovirus, levels. It also relates to kits and uses for said purposes. Furthermore, the invention relates to anthranilic acid for use in the treatment or prevention of food addiction, obesity and related disorders, and non-therapeutic use in body fat reduction.

CREB3 FOR THE TREATMENT OR THE PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: WO2026078185A1

The present invention relates to a composition comprising a c-AMP Response Element-Binding protein 3 (CREB3), in particular a variant of CREB3 protein, or a nucleic acid molecule encoding said CREB3 protein or said variant of CREB3 protein, for use as a medicament, in particular for treating or preventing diseases associated with a degeneration of motor neurons. The present invention further relates to CREB3 protein, in particular said variant of CREB3 protein, as a biomarker for the stratification or the prognosis of patients suffering, or susceptible of suffering, from a disease associated with a degeneration of motor neurons.

ヒト脳海馬領域における空間トランスクリプトミクスに基づくアルツハイマー病の診断及び鑑別診断のための方法、システム、組成物及び試薬キット

Resumen de: CN117761317A

According to the method, system, composition and kit for diagnosis and differential diagnosis of the Alzheimer's disease based on human brain hippocampus space transcriptomics, differential diagnosis of the Alzheimer's disease is achieved through one or more of CCK, Neurogranin and PMP2 carried by plasma extracellular vesicles (EVs). The core detection technology of the application is a nanoflow detection technology, focuses on clinical and scientific research problems of early diagnosis and differential diagnosis of AD cognitive impairment, and performs high-sensitivity and high-throughput detection on nervous system source EVs in peripheral blood through an international leading space transcriptome and single cell sequencing and a brand-new nanoflow detection technology; the method has the advantages of high speed and low cost, utilizes human brain resources, innovatively discovers the EVs markers of the brain region and cell specific sources of the central nervous system, realizes rapid and efficient early diagnosis and differential diagnosis of AD cognitive impairment, and provides a new technical means and method for clinical application of clinical AD cognitive impairment and large-scale screening related accurate diagnosis work.

ASSESSING AND TREATING PARANEOPLASTIC NEUROLOGIC SYNDROME

Resumen de: WO2024258729A2

This document provides methods and materials for assessing and/or treating mammals having a paraneoplastic neurologic syndrome (PNS). For example, methods and materials for using a Sloan Kettering virus family transcriptional corepressor 2 (SKOR2) polypeptide and/or one or more fragments of a SKOR2 polypeptide to detect the presence or absence of autoantibodies present in immune-mediated PNS are provided.

항-A-베타 단백질 항체, 이의 제조 방법 및 용도

Resumen de: MX2026001340A

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

ＣＤＫＬ５欠乏症のための治療

Resumen de: WO2024165736A1

Disclosed herein are methods and agents for the treatment and/or prevention of cyclin dependent kinase like 5 (CDKL5) deficiency disorder. In particular, disclosed herein are compounds or compositions for increasing cyclin dependent kinase like 2 (CDKL2) in a subject, such as in the brain of a subject, and the use of those compounds and compositions in methods of treating CDKL5 deficiency disorder

流体試料内に極微量に存在する分析対象物質の粒子を検出するための方法

Resumen de: KR102543112B1

The present invention relates to a method for detecting particles of a substance to be analyzed present in a minimum amount in a fluid sample. The method comprises the steps of: flowing a fluid sample containing a substance to be analyzed, on a substrate having an array of microchambers to the surface of which a first capture material specifically binding to the substance to be analyzed is fixed; allowing the substance to be analyzed to bind to the first capture material in each microchamber of the array of microchambers; flowing a second capture material specifically binding to the substance to be analyzed and binding to a signal generating material, on the substrate to react the substance to be analyzed with the second capture material; flowing the signal generating material on the substrate to bind to the second capture material; flowing, on the substrate, a substrate solution reacting with the signal generating material to generate a fluorescent signal; flowing a hydrophobic solvent on the substrate, and removing the substrate solution outside the microchamber when the signal generating material and the substrate solution react with each other inside the microchamber; and counting the number of microchambers in which the fluorescent signal has occurred, and detecting the same. Therefore, the concentration of molecules or particles present in a minimum amount in a fluid sample can be more easily calculated.

治疗认知损害的方法

Resumen de: WO2025064229A1

The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.

p-Tau205特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Resumen de: CN121851162A

0001 本申请公开了一种p‑Tau205特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域，本申请提供了靶向p‑Tau205的抗体、检测p‑Tau205的化学发光试剂盒。本申请的抗体亲和力高、灵敏度高和生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域。本申请公开的试剂盒可以用于与p‑Tau205相关的疾病，例如阿尔茨海默症的辅助诊断。

ニドゲンをベースとする足場タンパク質および治療用ナノ複合体

Resumen de: EP3842452A1

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

一种阿尔茨海默症筛查标志物、抗体、试剂盒及方法

Resumen de: CN121856567A

0001 本发明属于生物技术及医学检测技术领域，具体公开了一种阿尔茨海默症筛查标志物、抗体、试剂盒及方法，该筛查标志物为血浆外泌体中的SRC蛋白；所述抗体能特异性识别所述血浆外泌体中SRC蛋白；一种阿尔茨海默症筛查的方法包括：获取待测个体的血浆样本；从血浆样本中提取外泌体；使用抗体检测所述外泌体中SRC蛋白的表达水平；将表达水平和参考值进行比较，若表达水平高于参考值，则提示所述个体患有阿尔茨海默症的风险。本发明能无创对阿尔茨海默症进行早期筛查，且操作便捷、成本低、具有高敏感性和特异性。

一种基于EFEMP1检测辅助评估阿尔兹海默症早期风险的方法

Resumen de: CN121856564A

0001 本发明公开了一种基于EFEMP1检测辅助评估阿尔兹海默症早期风险的方法。所述方法为体外非诊断性分析方法，包括：对受试者的生物样本中EFEMP1的生物标志物水平进行检测，并基于检测结果获得用于评估该受试者AD早期风险的信息。所述生物标志物包括EFEMP1基因型、EFEMP1 mRNA表达水平或EFEMP1蛋白浓度。通过对血浆中EFEMP1蛋白浓度的定量检测来实现风险评估时，具体可采用包含针对EFEMP1蛋白不同表位的捕获抗体和检测抗体的免疫检测试剂盒进行。本发明通过检测受试者生物样本中EFEMP1的蛋白浓度、基因型或mRNA水平，获得用于风险判定的客观信息，实现了对AD上游病理机制的早期、无创监测，为疾病早期预警提供了新策略。

一种胶质瘤手术边界识别标志物及其应用

Resumen de: CN121852543A

本发明公开了一种胶质瘤手术边界识别标志物及其应用。本发明首次确认了SERPINA3可以作为识别胶质瘤侵袭边界的标志物，可以有效辅助胶质瘤术前或术中手术规划及肿瘤切除，提高手术切除精度，为胶质瘤临床诊断和治疗提供了有效分子工具，具有显著的应用前景。

一种基于GALNT10检测辅助评估阿尔兹海默症早期风险的方法

Resumen de: CN121852530A

0001 本发明公开了一种基于GALNT10检测辅助评估阿尔兹海默症早期风险的方法。所述方法为体外非诊断性分析方法，包括：对受试者的生物样本中GALNT10的生物标志物水平进行检测，并基于检测结果获得用于评估该受试者AD早期风险的信息。所述生物标志物包括GALNT10基因型、GALNT10 mRNA表达水平或GALNT10蛋白浓度。通过对血浆中GALNT10蛋白浓度的定量检测来实现风险评估时，具体可采用包含针对GALNT10蛋白不同表位的捕获抗体和检测抗体的免疫检测试剂盒进行。本发明通过检测受试者生物样本中GALNT10的蛋白浓度、基因型或mRNA水平，获得用于风险判定的客观信息，实现了对AD上游病理机制的早期、无创监测，为疾病早期预警提供了新策略。

インフラマソーム関連疾患又は病態を処置するための組成物及び方法

Resumen de: JP2026062733A

【課題】炎症性疾患の診断を支援可能なバイオマーカーとその使用方法。【解決手段】多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害のマーカーとして、対象からのサンプル中のインフラマソームの成分を検出するための組成物及び方法。多発性硬化症、脳卒中、軽度認知障害、アルツハイマー病、加齢性黄斑変性、ＮＡＳＨ、炎症性老化又は外傷性脳損傷などのインフラマソーム関連疾患又は障害を有する対象について、予後を判定し、処置を指示し、且つ処置に対する反応をモニタリングするためにかかるインフラマソームマーカーを使用する方法も記載される。【選択図】図３２

用于确定细胞中蛋白质及其衍生物的方法和工具

Nº publicación: CN121844211A 10/04/2026

Solicitante:

苏黎世联邦理工学院

Resumen de: WO2025056667A1

Method for the determination of at least one structural and/or physico-chemical property of at least one protein or peptide or of properties thereof, said at least one protein or peptide contained in a complex mixture of further proteins and/or other biomolecules in at least one cell, comprising the following steps: 1. delivery of a protease into said cell and limited proteolysis of the complex mixture, followed by cell extraction and/or cell lysis leading to a fragment sample; 2. denaturation of the fragment sample to a denaturated fragment sample; 3. optional complete fragmentation of the denaturated fragment sample in a digestion step to a completely fragmented sample; 4. analytical analysis of the fragmented sample or the completely fragmented sample for the determination of said at least one protein or peptide or of properties thereof.